A proteomic screen revealed that TGFβ is involved in the radioresistance phenotype, and TGFβ neutralizing antibody can inhibit the EMT and CSC phenotype, thus sensitizing tumor cells to RT and reducing tumorigenicity in vivo [51]. This evidence concerns the gene TGFB1 and neoplasm.